DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tysabri (Natalizumab) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

The most serious adverse reactions were [see Warnings and Precautions (5)]:

  • Progressive Multifocal Leukoencephalopathy (PML)
  • Hypersensitivity
  • Immunosuppression/Infections

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common adverse reactions (incidence ≥ 10%) were headache and fatigue in both the multiple sclerosis (MS) and Crohn's disease (CD) studies. Other common adverse reactions (incidence ≥ 10%) in the MS population were arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea NOS, and rash. Other common adverse reactions (incidence ≥ 10%) in the CD population were upper respiratory tract infections and nausea.

The most frequently reported adverse reactions resulting in clinical intervention (i.e., discontinuation of TYSABRI), in the MS studies were urticaria (1%) and other hypersensitivity reactions (1%), and in the CD studies (Studies CD1 and CD2) were the exacerbation of Crohn's disease (4.2%) and acute hypersensitivity reactions (1.5%) [see Warnings and Precautions (5.5)].

A total of 1617 multiple sclerosis patients in controlled studies received TYSABRI, with a median duration of exposure of 28 months. A total of 1563 patients received TYSABRI in all CD studies for a median exposure of 5 months; of these patients, 33% (n=518) received at least one year of treatment and 19% (n=297) received at least two years of treatment.

Multiple Sclerosis Clinical Studies

The most frequently reported serious adverse reactions in Study MS1 [see Clinical Studies (14.1)] with TYSABRI were infections (3.2% versus 2.6% in placebo, including urinary tract infection [0.8% versus 0.3%] and pneumonia [0.6% versus 0%]), acute hypersensitivity reactions (1.1% versus 0.3%, including anaphylaxis/anaphylactoid reaction [0.8% versus 0%]), depression (1.0% versus 1.0%, including suicidal ideation or attempt [0.6% versus 0.3%]), and cholelithiasis (1.0% versus 0.3%). In Study MS2, serious adverse reactions of appendicitis were also more common in patients who received TYSABRI (0.8% versus 0.2% in placebo).

Table 2 enumerates adverse reactions and selected laboratory abnormalities that occurred in Study MS1 at an incidence of at least 1 percentage point higher in TYSABRI-treated patients than was observed in placebo-treated patients.

Table 2: Adverse Reactions in Study MS1 (Monotherapy Study)
*Percentage based on female patients only.
** Acute versus other hypersensitivity reactions are defined as occurring within 2 hours post-infusion versus more than 2 hours.
Adverse Reactions
(Preferred Term)
TYSABRI
n=627
Percentage
Placebo
n=312
Percentage
General
      Headache
      Fatigue
      Arthralgia
      Chest discomfort
      Acute hypersensitivity reactions**
      Other hypersensitivity reactions**
      Seasonal allergy
      Rigors
      Weight increased
      Weight decreased

Infection
      Urinary tract infection
      Lower respiratory tract infection
      Gastroenteritis
      Vaginitis*
      Tooth infections
      Herpes
      Tonsillitis
     
Psychiatric
      Depression
     
Musculoskeletal/Connective Tissue Disorders
      Pain in extremity
      Muscle cramp
      Joint swelling

38%
27%
19%
5%
4%
5%
3%
3%
2%
2%


21%
17%
11%
10%
9%
8%
7%


19%


16%
5%
2%

33%
21%
14%
3%
<1%
2%
2%
<1%
<1%
<1%


17%
16%
9%
6%
7%
7%
5%


16%


14%
3%
1%
Gastrointestinal
      Abdominal discomfort
      Diarrhea NOS
      Abnormal liver function test
     
Skin
      Rash
      Dermatitis
      Pruritus
      Night sweats
     
Menstrual Disorders*
      Irregular menstruation
      Dysmenorrhea
      Amenorrhea
      Ovarian cyst

Neurologic Disorders
      Somnolence
      Vertigo


Renal and Urinary Disorders
      Urinary incontinence
      Urinary urgency/frequency

Injury
      Limb injury NOS
      Skin laceration
      Thermal burn


11%
10%
5%


12%
7%
4%
1%


5%
3%
2%
2%


2%
6%



4%
9%


3%
2%
1%

10%
9%
4%


9%
4%
2%
0%


4%
<1%
1%
<1%


<1%
5%



3%
7%


2%
<1%
<1%

In Study MS2, peripheral edema was more common in patients who received TYSABRI (5% versus 1% in placebo).

Crohn's Disease Clinical Studies

The following serious adverse events in the induction Studies CD1 and CD2 [see Clinical Studies (14.2)] were reported more commonly with TYSABRI than placebo and occurred at an incidence of at least 0.3%: intestinal obstruction or stenosis (2% vs. 1% in placebo), acute hypersensitivity reactions (0.5% vs. 0%), abdominal adhesions (0.3% vs. 0%), and cholelithiasis (0.3% vs. 0%). Similar serious adverse events were seen in the maintenance Study CD3. Table 3 enumerates adverse drug reactions that occurred in Studies CD1 and CD2 (median exposure of 2.8 months). Table 4 enumerates adverse drug reactions that occurred in Study CD3 (median exposure of 11.0 months).

Table 3: Adverse Reactions in Studies CD1 and CD2 (Induction Studies)
* Occurred at an incidence of at least 1% higher in TYSABRI-treated patients than placebo-treated patients.
** Percentage based on female patients only.
Adverse Reactions*
TYSABRI
n=983
Percentage
Placebo
n=431
Percentage
General
      Headache
      Fatigue
      Arthralgia
      Influenza-like illness
      Acute hypersensitivity reactions
      Tremor


Infection
      Upper respiratory tract infection
      Vaginal infections**
      Viral infection
      Urinary tract infection


Respiratory
      Pharyngolaryngeal pain
      Cough


Gastrointestinal
      Nausea
      Dyspepsia
      Constipation
      Flatulence
      Aphthous stomatitis


Skin
      Rash
      Dry skin

Menstrual Disorder
      Dysmenorrhea**

32%
10%
8%
5%
2%
1%



22%
4%
3%
3%



6%
3%



17%
5%
4%
3%
2%



6%
1%


2%

23%
8%
6%
4%
<1%
<1%



16%
2%
2%
1%



4%
<1%



15%
3%
2%
2%
<1%



4%
0%


<1%
Table 4: Adverse Reactions in Study CD3 (Maintenance Study)
* Occurred at an incidence of at least 2% higher in TYSABRI-treated patients than placebo-treated patients.
** Percentage based on female patients only.
Adverse Reactions*
TYSABRI
n=214
Percentage
Placebo
n=214
Percentage
General
      Headache
      Influenza-like illness
      Toothache
      Peripheral edema


Infection
      Influenza
      Sinusitis
      Viral infection
      Vaginal infections**


Respiratory
      Cough

Gastrointestinal
      Lower abdominal pain

Musculoskeletal and Connective Tissue
      Back pain

Menstrual Disorder
      Dysmenorrhea**

37%
11%
4%
6%



12%
8%
7%
8%



7%


4%


12%


6%

31%
6%
<1%
3%



5%
4%
3%
<1%



5%


2%


8%


3%

Infections

Progressive Multifocal Leukoencephalopathy (PML) occurred in three patients who received TYSABRI in clinical trials [see Warnings and Precautions (5.1)]. Two cases of PML were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks. These two patients had received TYSABRI in addition to interferon beta-1a [see Warnings and Precautions (5.1)]. The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML. In the postmarketing setting, additional cases of PML have been reported in TYSABRI-treated multiple sclerosis and Crohn's disease patients who were not receiving concomitant immunomodulatory therapy.

In Studies MS1 and MS2 [see Clinical Studies (14.1)], the rate of any type of infection was approximately 1.5 per patient-year in both TYSABRI-treated patients and placebo-treated patients. The infections were predominately upper respiratory tract infections, influenza, and urinary tract infections. In Study MS1, the incidence of serious infection was approximately 3% in TYSABRI-treated patients and placebo-treated patients. Most patients did not interrupt treatment with TYSABRI during infections. The only opportunistic infection in the multiple sclerosis clinical trials was a case of cryptosporidial gastroenteritis with a prolonged course.

In Studies CD1 and CD2 [see Clinical Studies (14.2)], the rate of any type of infection was 1.7 per patient-year in TYSABRI-treated patients and 1.4 per patient-year in placebo-treated patients. In Study CD3, the incidence of any type of infection was 1.7 per patient-year in TYSABRI-treated patients and was similar in placebo-treated patients. The most common infections were nasopharyngitis, upper respiratory tract infection, and influenza. The majority of patients did not interrupt TYSABRI therapy during infections and recovery occurred with appropriate treatment. Concurrent use of TYSABRI in CD clinical trials with chronic steroids and/or methotrexate, 6-MP, and azathioprine did not result in an increase in overall infections compared to TYSABRI alone; however, the concomitant use of such agents could lead to an increased risk of serious infections.

In Studies CD1 and CD2, the incidence of serious infection was approximately 2.1% in both TYSABRI-treated patients and placebo-treated patients. In Study CD3, the incidence of serious infection was approximately 3.3% in TYSABRI-treated patients and approximately 2.8% in placebo-treated patients.

In clinical studies for CD, opportunistic infections (pneumocystis carinii pneumonia, pulmonary mycobacterium avium intracellulare, bronchopulmonary aspergillosis, and burkholderia cepacia) have been observed in <1% of TYSABRI-treated patients; some of these patients were receiving concurrent immunosuppressants [see Warnings and Precautions (5.6)]. Two serious non-bacterial meningitides occurred in TYSABRI-treated patients compared to none in placebo-treated patients.

Infusion-related Reactions

An infusion-related reaction was defined in clinical trials as any adverse event occurring within two hours of the start of an infusion. In MS clinical trials, approximately 24% of TYSABRI-treated multiple sclerosis patients experienced an infusion-related reaction, compared to 18% of placebo-treated patients. In the controlled CD clinical trials, infusion-related reactions occurred in approximately 11% of patients treated with TYSABRI compared to 7% of placebo-treated patients. Reactions more common in the TYSABRI-treated MS patients compared to the placebo-treated MS patients included headache, dizziness, fatigue, urticaria, pruritus, and rigors. Acute urticaria was observed in approximately 2% of patients. Other hypersensitivity reactions were observed in 1% of patients receiving TYSABRI. Serious systemic hypersensitivity infusion reactions occurred in <1% of patients [see Warnings and Precautions (5.5)]. All patients recovered with treatment and/or discontinuation of the infusion.

Infusion-related reactions more common in CD patients receiving TYSABRI than those receiving placebo included headache, nausea, urticaria, pruritus, and flushing. Serious infusion reactions occurred in Studies CD1, CD2, and CD3 at an incidence of <1% in TYSABRI-treated patients.

MS and CD patients who became persistently positive for antibodies to TYSABRI were more likely to have an infusion-related reaction than those who were antibody-negative.

Immunogenicity

Patients in Study MS1 [see Clinical Studies (14.1)] were tested for antibodies to natalizumab every 12 weeks. The assays used were unable to detect low to moderate levels of antibodies to natalizumab. Approximately 9% of patients receiving TYSABRI developed detectable antibodies at least once during treatment. Approximately 6% of patients had positive antibodies on more than one occasion. Approximately 82% of patients who became persistently antibody-positive developed detectable antibodies by 12 weeks. Anti-natalizumab antibodies were neutralizing in vitro.

The presence of anti-natalizumab antibodies was correlated with a reduction in serum natalizumab levels. In Study MS1, the Week 12 pre-infusion mean natalizumab serum concentration in antibody-negative patients was 15 mcg/mL compared to 1.3 mcg/mL in antibody-positive patients. Persistent antibody-positivity resulted in a substantial decrease in the effectiveness of TYSABRI. The risk of increased disability and the annualized relapse rate were similar in persistently antibody-positive TYSABRI-treated patients and patients who received placebo. A similar phenomenon was also observed in Study MS2.

Infusion-related reactions most often associated with persistent antibody-positivity included urticaria, rigors, nausea, vomiting, headache, flushing, dizziness, pruritus, tremor, feeling cold, and pyrexia. Additional adverse reactions more common in persistently antibody-positive patients included myalgia, hypertension, dyspnea, anxiety, and tachycardia.

Patients in CD studies [see Clinical Studies (14.2)] were first tested for antibodies at Week 12, and in a substantial proportion of patients, this was the only test performed given the 12-week duration of placebo-controlled studies. Approximately 10% of patients were found to have anti-natalizumab antibodies on at least one occasion. Five percent (5%) of patients had positive antibodies on more than one occasion. Persistent antibodies resulted in reduced efficacy and an increase in infusion-related reactions with symptoms that include urticaria, pruritus, nausea, flushing, and dyspnea.

The long-term immunogenicity of TYSABRI and the effects of low to moderate levels of antibody to natalizumab are unknown [see Warnings and Precautions (5.5), Adverse Reactions (6.1)].

Immunogenicity data are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody-positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to TYSABRI with the incidence of antibodies to other products may be misleading.

DRUG INTERACTIONS

Because of the potential for increased risk of PML and other infections, Crohn's disease patients receiving TYSABRI should not be treated with concomitant immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-α, and corticosteroids should be tapered in those patients with Crohn's disease who are on chronic corticosteroids when they start TYSABRI therapy [see Indications and Usage (1.2), Warnings and Precautions (5.1, 5.6)]. Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYSABRI [see Indications and Usage (1.1), Warnings and Precautions (5.1, 5.6)].



REPORTS OF SUSPECTED TYSABRI SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Tysabri. The information is not vetted and should not be considered as verified clinical evidence.

Possible Tysabri side effects / adverse reactions in 58 year old female

Reported by a consumer/non-health professional from United States on 2011-10-03

Patient: 58 year old female

Reactions: Gait Disturbance

Suspect drug(s):
Tysabri



Possible Tysabri side effects / adverse reactions in 27 year old male

Reported by a consumer/non-health professional from United States on 2011-10-03

Patient: 27 year old male

Reactions: Stress

Suspect drug(s):
Tysabri



Possible Tysabri side effects / adverse reactions in 60 year old male

Reported by a consumer/non-health professional from United States on 2011-10-03

Patient: 60 year old male

Reactions: Infusion Site Haematoma

Suspect drug(s):
Tysabri



See index of all Tysabri side effect reports >>

Drug label data at the top of this Page last updated: 2013-12-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017